Company intelligence / Profile preview
Tafalgie Therapeutics
Marseille, Provence-Alpes-Côte d'Azur, Francetafalgie.fr ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
Tafalgie Therapeutics has demonstrated analgesic efficacy equivalent to morphine and opioids like methadone in preclinical models, but without the adverse effects or development of tolerance. Their lead molecules are progressing toward first-in-human trials. The approach is based on a novel mechanism involving endogenous TAFA4 protein modulation.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SATT Sud Est technology transfer office
Beyond the preview
Go deeper on Tafalgie Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tafalgie Therapeutics.